Predictors of response to potassium channel blockade in chronically paralyzed dogs
Acute spinal cord injuries are a common problem in dogs, and some dogs fail to recover and are left permanently paralyzed and incontinent. In prior clinical trials, we have shown that chronically paralyzed dogs have extremely variable responses to the potassium channel-blocking drug, 4-aminopyridine (4-AP). Some treated dogs improve to the point of walking while others show no response despite having suffered from very similar initial injuries. The aim of this trial is to identify the factors that predict response to this therapy in dogs with incomplete recovery following acute spinal cord injuries allowing optimization of individual therapy regimens. For more information...
Recruiting Cavalier King Charles Spaniels for two studies on Chiari-like Malformations and Syringomyelia (CM/SM)
Cavalier King Charles Spaniels (CKCS) are predisposed to skull malformations (called Chiari-like malformations, CM) that are associated with syringomyelia (SM) producing chronic pain. In this study we seek to quantify thresholds to temperature and touch in dogs with and without CM/SM and also perform genetic analysis to identify genes associated with the condition. This study is funded by the AKC Canine Health Foundation and supported by the American Cavalier King Charles Spaniel Club. For more information...
Completed Clinical Trials
Chronic Paralyis and Potassium Channel Blockers
We recently published the results of a clinical trial looking at the effect of potassium channel blockers on walking ability in chronically paralyzed dogs.
While we were able to show a significant improvement in walking, the most important finding of the study was that a small number of dogs showed a dramatic response going from unable to walk, to independent stepping. Our ongoing work is focusing on identifying factors that predict a response to these drugs and we will be recruiting dogs that failed to recover from acute disc herniations or traumatic injuries. The hope is that we can develop ways to target the most appropriate treatment to individual dogs.
The paper is open access and can be found here:
This trial evaluated two different potassium channel blockers in chronically paralyzed dogs due to an acute spinal cord injury. Dogs in this trial had been unable to use their hind limbs due to a thoracolumbar spinal cord injury that had occurred at least 6 months previously. This trial was funded by NeuroMetrix Inc.
A Phase 1 clinical trial of GGF2 in dogs with disc-induced acute spinal cord injuries *Data analysis is being completed and the results of this study will be submitted for publication shortly
Acute spinal cord injuries are a common problem in dogs, and due to the poor regenerative capacity of the nervous system, some dogs fail to recover and are left permanently paralyzed and incontinent. Experimental studies in rodents suggest that Glial Growth Factor 2 (GGF2) improves the recovery from a spinal cord injury. The purpose of this clinical trial is to evaluate the safety of GGF2 in dogs with severe spinal cord injuries due to acute intervertebral disc herniations. For more information..
Methylprednisolone Sodium Succinate and Polyethylene Glycol in Canine Spinal Cord Injury. *Data analysis is being completed and the results of this study will be submitted for publication shortly
This was a multicenter trial for dogs that suffered an acute spinal cord injury due to a disc herniation. Two different neuroprotective drugs were used compared with placebo in surgically treated dogs. Dogs entered into this trial were paraplegic with no pain sensation in their hind feet, weighed less than 20kg, were between 2 and 10 years, and had suffered the injury within 24 hours of presentation. Sixteen centers across the US were involved in the trial. This trial was funded by Morris Animal Foundation. For more information...
Treatment of paraparesis in dogs using a novel derivative of 4-aminopyridine.*Data analysis has been completed and the results of this study will be submitted for publication shortly
This trial compared the effect of the t-butyl derivative of 4-AP and placebo on hind limb gait in chronically paraparetic dogs. Dogs entered into this trial must have chronic neurologic deficits in their pelvic limbs as a result of an acute spinal cord injury at least 6 months previously. Some dog had some motor function in their hind limbs, but had an obviously abnormal hind limb gait. This trial was funded by Morris Animal Foundation For more information...
Treatment of Canine Paralysis with Autologous Adipose Tissue Derived Stem Cells, Schwann Cells & Inosine.
*Data analysis has been completed and the results of this study will be submitted for publication shortly
This trial evaluated the effect of combining transplants of autologous (derived from the patient) Schwann cells (SCs) and Adipose Derived Stromal cells (ADSCs) with an inosine infusion in chronically paralyzed dogs. For inclusion in this trial, dogs were unable to use their hind limbs due to a thoracolumbar spinal cord injury that had occurred at least 3 months previously. This trial was funded by Morris animal Foundation. For more information...
The Effect of Cranberry Extract on Myelopathy-Associated Urinary Tract Infections in Dogs. *Case recruitment is complete and data analysis is ongoing
Spinal cord injuries affect not only movement of the hind limbs, but also the ability to urinate. While dogs recover from a spinal cord injury they are predisposed to develop urinary tract infections (UTIs) because of a failure to empty their bladder completely. Cranberry extract has been shown to reduce the chance of developing a UTI by preventing certain common types of bacteria from adhering to the bladder wall. In this study we compared the effect of cranberry extract with placebo on the incidence of UTIs. This study was funded by Morris Animal Foundation. For more information ...